Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1498-1501

  Wells, Charles D ^a   Gupta, Rajesh ^a   Hittel, Norbert ^b   Geiter, Lawrence J ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b Otsuka Novel Products GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DELAMANID; PLACEBO; BIOLOGICAL MARKER; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE;

HUMAN; LETTER; LONG TERM CARE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SPUTUM CULTURE; SPUTUM CULTURE CONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; CONTROLLED STUDY; FOLLOW UP; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

BIOMARKERS; FOLLOW-UP STUDIES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84922970028     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00176314     Document Type: Letter

References (15)

1. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
2. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
3. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205: Suppl. 2, S241-S249.
4. Ryan NJ, Lo JH. Delamanid: first global approval. Drugs 2014; 74: 1041-1045.
5. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
6. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2012; 41: 1393-1400.
7. Mitchison DA. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 2004; 25: 307-315.
8. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Administration and Research. Guidance for Industry Pulmonary Tuberculosis: Developing Drugs for Treatment. Washington, DC, United States Health and Human Services, 2013.
9. Committee for Medical Products for Human Use. Addendum to the Note for Guidance on Evaluation of Medicinal Products Indicated for the Treatment of Bacterial Infections to Specifically Address Clinical Development of New Agents to Treat Disease Due to Mycobacterium Tuberculosis. London, European Medicines Agency, 2008.
10. Gammino VM, Taylor AB, Rich ML, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011; 15: 1315-1322.
11. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.
12. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
13. Kurbatova EV, Taylor A, Gammino VM, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) 2012; 92: 397-403.
14. Diacon AH, von Groote-Bidlingmaier F, Donald PR. Delamanid, a new 6-nitro-2, 3-dihydroimidazo[2, 1-b] oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Expert Opin Orphan Drugs 2014; 2: 87-94.
15. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.